Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups

References

• Braun, T. M. 2002. The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes. Controlled Clinical Trials 23 (3):240–256.
   PubMedGoogle Scholar
• Chen, Z., Yuan, Y., Li, Z., et al. 2015. Dose escalation with over-dose and under-dose controls in phase I/II clinical trials. Contemporary Clinical Trials 43:133–141. doi:10.1016/j.cct.2015.05.014.
   PubMed Web of Science ®Google Scholar
• Cheung, Y. K., and R. Chappell. 2000. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56:1177–1182.
   PubMed Web of Science ®Google Scholar
• Dunson, D. B., and B. Neelon. 2003. Bayesian inference on order-constrained parameters in generalized linear models. Biometrics 59:286–295.
   PubMed Web of Science ®Google Scholar
• Gooley, T. A., P. J. Martin, L. D. Fisher, and M. Pettinger. 1994. Simulation as a design tool for phase I/II clinical trials: An example from bone marrow transplantation. Controlled Clinical Trials 15:450–462. doi:10.1016/0197-2456(94)90003-5.
   PubMedGoogle Scholar
• Innocenti, F., S. D. Undevia, L. Iyer, P. X. Chen, S. Das, M. Kocherginsky, T. Karrison, L. Janisch, J. Ramirez, C. M. Rudin, et al. 2004. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Journal of Clinical Oncology 22 (8):1382–1388. doi:10.1200/JCO.2004.07.173.
   PubMed Web of Science ®Google Scholar
• Ivanova, A. 2003. A new dose-finding design for bivariate outcomes. Biometrics 59:1001–1007.
   PubMed Web of Science ®Google Scholar
• Ivanova, A., and K. Wang. 2006. Bivariate isotonic design for dose-finding with ordered groups. Statistics in Medicine 25:2018–2026. doi:10.1002/sim.2312.
   PubMed Web of Science ®Google Scholar
• Ivanova, A., Y. Wang, and M. C. Foster. 2016. The rapid enrollment design for phase I clinical trials. Statistics in Medicine 35 (15):2516–2524. doi:10.1002/sim.6886.
   PubMed Web of Science ®Google Scholar
• Lee, D. W., J. N. Kochenderfer, M. Stetler-Stevenson, Y. K. Cui, C. Delbrook, S. A. Feldman, T. J. Fry, R. Orentas, M. Sabatino, N. N. Shah, et al. 2015. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517–528. doi:10.1016/S0140-6736(14)61403-3.
   PubMed Web of Science ®Google Scholar
• Li, W., S. D. Durham, and N. Flournoy. 1995. An adaptive design for maximization of a contingent binary response. In New developments and applications in experimental design, ed. N. Flournoy, W. F. Roserberger, and W. K. Wong, 50–61. Hayward, CA: Institute of Mathematical Statistics.
   Google Scholar
• Murtaugh, P. A., and L. D. Fisher. 1990. Bivariate binary models of efficacy and toxicity in dose-ranging trials. Communications in Statistics. Theory and Methods. 19 (6):2003–2020. doi:10.1080/03610929008830305.
   Web of Science ®Google Scholar
• Naidoo, J., D. B. Page, B. T. Li, L. C. Connell, K. Schindler, M. E. Lacouture, M. A. Postow, and J. D. Wolchok. 2015. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology 26 (12):2375.
   PubMed Web of Science ®Google Scholar
• Neelapu, S. S., S. Tummala, P. Kebriaei, W. Wierda, C. Gutierrez, F. L. Locke, K. V. Komanduri, Y. Lin, N. Jain, N. Daver, et al. Jan 2018. Chimeric antigen recepotor T-cell therapy – Assessment and management of toxicities. Nature Reviews Clinical Oncology 15(1):47–62. doi: 10.1038/nrclinonc.2017.148.
   PubMed Web of Science ®Google Scholar
• O’Guiley, J., M. D. Huges, and T. Fenton. 2001. Dose-finding designs for HIV studies. Biometrics 57:1018–1029.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., and X. Paoletti. 2003. Continual reassessment method for ordered groups. Biometrics 59:430–440.
   PubMed Web of Science ®Google Scholar
• R Core Team. 2017. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. https://www.R-project.org/.
   Google Scholar
• Salter, A., J. O’Quigley, G. R. Cutter, and I. B. Aban. 2015. Two-group time-to event continual reassessment method using likelihood estimation. Contemporary Clinical Trials 45:340–345. doi:10.1016/j.cct.2015.09.016.
   PubMed Web of Science ®Google Scholar
• Sato, H., A. Hirakawa, and C. Hamada. 2016. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. Statistics in Medicine 35 (23):4093–4109. doi:10.1002/sim.6981.
   PubMed Web of Science ®Google Scholar
• Sverdlov, O., W. K. Wong, and Y. Ryeznik. 2014. Adaptive clinical trial designs for phase I cancer studies. Statistics Surveys 8:2–44. doi:10.1214/14-SS106.
   Google Scholar
• Thall, P. F., and J. D. Cook. 2004. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60 (3):684–693. doi:10.1111/j.0006-341X.2004.00218.x.
   PubMed Web of Science ®Google Scholar
• Thall, P. F., and K. E. Russell. 1998. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54 (1):251–264.
   PubMed Web of Science ®Google Scholar
• Tighiouart, M., Y. Liu, and A. Rogatko. 2014Mar24.Escalation with overdose control using time to toxicity for cancer phase I clinical trials. PLoS One 93: e93070.doi: 10.1371/journal.pone.0093070
   PubMed Web of Science ®Google Scholar
• Weber, J. S., J. C. Yang, M. B. Atkins, and M. L. Disis. 2015. Toxicities of immunotherapy for the practitioner. Journal of Clinical Oncology 33:2092–2099. doi:10.1200/JCO.2014.60.0379.
   PubMed Web of Science ®Google Scholar
• Zhou, X., G. Dotti, R. A. Krance, C. A. Martinez, S. Naik, R. T. Kamble, A. G. Durett, O. Dakhova, B. Savoldo, A. Di Stasi, et al. 2015. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood 125 (26):4103–4113. doi:10.1182/blood-2015-02-628354.
   PubMed Web of Science ®Google Scholar